Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, toward future clinical studies, marking a significant step in addressing treatment resistance in cancer. The company has achieved kilogram-scale manufacturing of a key precursor for ONC010’s active pharmaceutical ingredient, enabling formulation development, GMP production, and clinical trial preparation. This milestone supports the broader strategy to build the infrastructure needed for first-in-human studies.
ONC010 is a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms, potentially overcoming resistance to existing therapies. The company’s recent activities include signing a letter of intent with Nanosoft Polymers to advance polymer development and drug delivery optimization, as well as engagements with Nucro-Technics for bioanalytical development and Avance Clinical for clinical and regulatory planning. These partnerships are critical for advancing the candidate’s formulation and regulatory pathway.
The importance of this development lies in the urgent need for novel cancer treatments that can target resistant tumors. PNKP inhibitors represent a promising approach by exploiting vulnerabilities in cancer cell DNA repair, which could enhance the efficacy of chemotherapy and radiation. Onco-Innovations’ progress in manufacturing and partnerships positions it to move ONC010 through the preclinical-to-clinical transition, a key hurdle in oncology drug development.
Onco-Innovations is a Canadian-based company dedicated to cancer research, holding an exclusive worldwide license to patented technology targeting solid tumors. The company’s mission focuses on pioneering research and innovative solutions for cancer prevention and treatment. For more information, visit the company’s website at https://oncoinnovations.com/.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. As Onco-Innovations continues to advance ONC010, the oncology community will be watching for clinical data that could validate the PNKP inhibition approach and offer new options for patients with treatment-resistant cancers.
